Enliven Therapeutics (ELVN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.49
- Estimate
- -$0.36
- Surprise
- -37.4%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Enliven Therapeutics (ELVN) reported a wider loss than forecast — adjusted EPS of -$0.49 against the -$0.36 estimate (a 37.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ELVN Sell at 5.4/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -37.4% surprise compares with a +1.9% four-quarter average. Next scheduled report: 2026-11-11.
What argues against it
- Concentration risk — Pipeline: ELVN-001
- Concentration risk — Supplier: Pharmaron
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $40.98
- Price target
- $64.09
- Stop
- $38.11
- Upside to target
- +56.4%
- Reward-to-risk
- 5.9:1
Risk check: RSI 23 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-11 — shown for context, not personalized investment advice.
ELVN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.00B
- P/E (fwd)
- -17.4
- 52-week range
- $14.79–$62.32
- Off 52-week high
- 34.2%
- RSI (14)
- 23
- Volume vs avg
- 0.63×
- Score today
- 5.4/10